This trial is testing a combination of two drugs to treat estrogen receptor-positive breast cancer. The goal is to find the maximum tolerated dose and/or the recommended Phase 2 dose of the combination.
1 Primary · 21 Secondary · Reporting Duration: From first dose of study drug up to Month 24
Experimental Treatment
36 Total Participants · 1 Treatment Group
Primary Treatment: Palbociclib (75, 100, 125 milligram [mg]) · No Placebo Group · Phase 1
Age 18+ · Female Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: